Financial Assets and Financial Liabilities (Tables)

12 Months Ended

Jun. 30, 2026

Non-Financial Assets and Liabilities [Abstract]

Schedule of Cash and Cash Equivalents

(a) Cash and cash equivalents

		30 June 2026 $				30 June 2025 $				30 June 2024 $
Current assets
Cash at bank and on hand			4,138,074				29,116,835				18,575,040
			4,138,074				29,116,835				18,575,040

Schedule of Consolidated Statement of Cash Flows

The above figures reconcile to the amount of cash shown in the consolidated statement of cash flows at the end of the financial year and period, respectively, as follows:

		30 June 2026 $				30 June 2025 $				30 June 2024 $
Balances as above
Balances per statement of cash flows			4,138,074				29,116,835				18,575,040
			4,138,074				29,116,835				18,575,040

Schedule of Trade and Other Receivables

(b) Trade and other receivables

		30-Jun-26												30-Jun-25												30-Jun-24
						Non-												Non-												Non-
		Current				current				Total				Current				current				Total				Current				current				Total
		$				$				$				$				$				$				$				$				$
Trade receivables			1,227,040				-				1,227,040								-				-				-				-				-
Accrued receivables (i)			15,877,895				-				15,877,895				10,171,532				-				10,171,532				802,988				-				802,988
Other receivables			342,493				-				342,493				228,528				-				228,528				184,425				-				184,425
			17,447,428				-				17,447,428				10,400,060				-				10,400,060				987,413				-				987,413

(i) Accrued receivables

Accrued receivables comprise $15,877,895 from the Australian Taxation Office in relation to the R&D tax incentive (30 June 2025: $10,171,532).

Schedule of Trade and Other Payables

(c) Trade and other payables

				30-Jun-25												30-Jun-25												30-Jun-24
								Non-												Non-												Non-
				Current				current				Total				Current				current				Total				Current				current				Total
		Notes		$				$				$				$				$				$				$				$				$
Trade payables					5,466,476				-				5,466,476				6,347,397				-				6,347,397				6,434,524				-				6,434,524
Amounts due to employees		15(b)			-				-				-				-				-				-				490,335				-				490,335
Accrued expenses					4,836,856				-				4,836,856				2,750,662				-				2,750,662				1,680,442				-				1,680,442
Other payables					228,468				-				228,468				242,934								242,934				248,302				-				248,302
R&D advance					-				-				-				-				-				-				2,003,190				-				-
					10,531,800				-				10,531,800				9,340,993				-				9,340,993				10,856,793				-				8,853,603

Schedule of Other Financial Liabilities

(d) Other financial liabilities

		30 June 2026												30 June 2025
		Current				Non- current				Total				Current				Non- current				Total
		$				$				$				$				$				$
Diaprost contingent consideration			1,979,902				6,916,482				8,896,384				1,328,087				8,841,829				10,169,916
NanoMab contingent consideration⁽¹⁾			4,502,764				1,050,443				5,553,207				1,832,833				4,899,858				6,732,691
NeoIndicate contingent consideration⁽²⁾			-				-				-				-				1,870,454				1,870,454
Pivalate contingent consideration			378,184				1,646,950				2,025,134				225,245				1,933,981				2,159,226
Pharma15 deferred consideration⁽³⁾			-				-				-				-				-				-
Pharma15 contingent consideration			-				-				-				-				1,134,164				1,134,164
TRIMT contingent consideration			-				7,758,256				7,758,256				-				8,423,667				8,423,667
UCLA contingent consideration			-				-				-				-				-				-
MD Anderson contingent consideration			-				1,540,798				1,540,798				35,172				1,573,034				1,608,206
Advanced payment liability			-				-				-				-				-				-
			6,860,850				18,912,929				25,773,779				3,421,337				28,676,987				32,098,324

(1)	Payment to be made in the form of ordinary shares in the company, based on the price of the 7-day volume weighted average price (VWAP) prior to the announcement of the milestone on the ASX.
(2)	The NeoIndicate asset was handed back to the university during the financial year, resulting in the unwinding of contingent consideration for its milestone payments.
(3)	The Pharma15 asset was fully impaired during the year and as a result the likelihood of milestones being met for the progression of the asset has been also reduced to nil.

Schedule of Financial Liabilities with Significant Estimation Uncertainty

(e) Financial liabilities with significant estimation uncertainty

		Total
At 30 June 2026		$
Financial Liabilities
NanoMab contingent consideration			5,553,207
Diaprost contingent consideration			8,896,384
TRIMT contingent consideration			7,758,256
Pivalate contingent consideration			2,025,134
NeoIndicate contingent consideration			-
Pharma15 contingent consideration			-
MD Anderson contingent consideration			1,540,798
Advance payment liability			-
Total financial liabilities			25,773,779

		Total
At 30 June 2025		$
Financial Liabilities
NanoMab contingent consideration			6,732,691
Diaprost contingent consideration			10,169,916
TRIMT contingent consideration			8,423,667
Pivalate contingent consideration			2,159,226
NeoIndicate contingent consideration			1,870,454
Pharma15 contingent consideration			1,134,164
Pharma15 deferred consideration			-
MD Anderson contingent consideration			1,608,206
Total financial liabilities			32,098,324